Meta Information
ID:ceramides
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/dietary/high-fat-meal
Target name:
Meal Containing Fat
Severity:
major
Interaction type:
requirement
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Ceramides are lipid molecules and require the presence of dietary fat and bile acids in the small intestine for proper emulsification and absorption.
Actionable advice:
Oral ceramides should be taken during or immediately after a meal that contains healthy fats.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Established lipid physiology: ceramides are sphingolipids whose intestinal absorption depends on dietary fat and bile-acid emulsification, so taking them with a fat-containing meal improves uptake. (Original citation was a vendor blog, discarded; mechanism is sound.)
Label source:
Class inference
Action type:
separate
Target id:
/intervention/orlistat
Target name:
Orlistat (Fat Absorption Inhibitor)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Orlistat functions by blocking pancreatic lipase, the enzyme that breaks down dietary fats for absorption. This will prevent the absorption of ceramide supplements.
Actionable advice:
Oral ceramides should not be taken while using Orlistat, as they will not be effective.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
11 DESCRIPTION
11 DESCRIPTION XENICAL (orlistat) is a gastrointestinal lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats.
Label source:
Action type:
avoid
Target id:
/class/bile-acid-sequestrants
Target name:
Bile Acid Sequestrants
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
4
Hours after target:
4
Description:
These medications are designed to bind bile acids and other lipids in the gut, which will bind to and prevent the absorption of ceramide supplements.
Actionable advice:
Ceramides and bile acid sequestrants should be separated by at least 4 hours.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Because cholestyramine binds bile acids, QUESTRAN may interfere with normal fat digestion
and absorption and thus may prevent absorption of fat-soluble vitamins such as A, D, E and
K.
Label source:
Action type:
separate
Target id:
/intervention/ezetimibe
Target name:
Ezetimibe
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
4
Description:
Ezetimibe inhibits the absorption of cholesterol and other lipids from the small intestine, which is likely to reduce the uptake of oral ceramide supplements.
Actionable advice:
Ceramides are best taken at least 2 hours before or 4 hours after ezetimibe to minimize interaction.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
( 2 )
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine.
Label source:
Action type:
separate
Target id:
/class/viscous-fibers
Target name:
Gel-Forming Viscous Fibers
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
High doses of soluble, gel-forming fibers like psyllium, glucomannan, or beta-glucan can trap lipids in the gut, potentially reducing ceramide absorption.
Actionable advice:
Doses of ceramides and high-dose viscous fiber supplements should be separated by at least 2 hours.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
In this meta-analysis, we investigated whether the concomitant use of psyllium, a gel-forming viscous soluble fiber, would cause further overall cholesterol lowering in subjects already receiving statins.
Label source:
PubMed: Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins. (PMID 30078477)
Action type:
separate
Target id:
/intervention/tretinoin
Target name:
Topical Retinoids (e.g., Tretinoin)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Oral ceramides help strengthen the skin barrier from within, which can improve tolerance and reduce the dryness, peeling, and irritation often caused by topical retinoids.
Actionable advice:
Consider taking oral ceramides to support your skin barrier and improve tolerance when using topical retinoids.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Unvalidatable: oral ceramides improving topical-retinoid tolerance is speculative with no supporting human evidence.
Action type:
informational_none
Target id:
/class/exfoliating-acids
Target name:
Topical Exfoliating Acids (AHAs, BHAs)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
By improving the skin's natural barrier function and hydration, oral ceramides can help mitigate potential irritation and sensitivity from chemical exfoliants like glycolic or salicylic acid.
Actionable advice:
Oral ceramides may help skin better tolerate exfoliating acid treatments.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Unvalidatable: oral ceramides mitigating exfoliant irritation is speculative with no supporting human evidence.
Action type:
informational_none
Target id:
/biomarker/plasma-ceramides-test
Target name:
Plasma Ceramides Test
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Taking oral ceramide supplements will directly increase the levels of ceramides in your blood, confounding the results of tests used to measure endogenous ceramide levels for cardiovascular risk assessment.
Actionable advice:
Ceramide supplements should be discontinued for at least one week before a plasma ceramides blood test for an accurate baseline reading.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Logical inference: oral ceramide supplementation could raise plasma ceramide species and confound the clinical plasma-ceramide cardiac risk panel (a real, authoritative test). No study directly demonstrates the magnitude, so class-inference; advise spacing/disclosure before testing.
Label source:
Class inference
Action type:
avoid
Target id:
/condition/fat-malabsorption
Target name:
Fat Malabsorption Conditions
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Medical conditions that impair the body's ability to absorb dietary fats, such as Crohn's disease, celiac disease, or pancreatic insufficiency, will prevent oral ceramides from being absorbed and utilized.
Actionable advice:
Oral ceramide supplements are unlikely to be effective if you have a condition that significantly impairs fat absorption.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Established physiology: conditions causing fat malabsorption (pancreatic insufficiency, bile-acid deficiency, Crohn's, celiac) impair absorption of dietary lipids including ceramides, reducing their bioavailability.
Label source:
Class inference
Action type:
informational_none
Target id:
/class/statins
Target name:
Statins
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Statins can alter the body's own ceramide metabolism, and high levels of certain ceramides are associated with cardiovascular risk. The interaction is theoretical but warrants caution.
Actionable advice:
If taking statins, discuss ceramide supplementation with your doctor and continue to monitor your cardiovascular health markers.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
There have been rare reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia,
memory impairment, confusion) associated with the use of all statins.
Label source:
Action type:
monitor
Target id:
/condition/diabetes-mellitus
Target name:
Diabetes or Insulin Resistance
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Elevated levels of certain endogenous ceramides are biologically linked to the development of insulin resistance. While plant-derived supplements are generally considered safe, caution is advised.
Actionable advice:
It is a good idea to talk to a physician before using ceramide supplements with diabetes or metabolic syndrome.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
The sphingolipid ceramide is the main culprit that combines a plethora of nutrients (e.g., saturated fatty acids) and inflammatory cytokines (e.g., TNFalpha) to the progression of insulin resistance.
Label source:
Review on ceramides in insulin resistance, PMC6712072. Supports elevated endogenous ceramides being linked to insulin resistance (note: concerns endogenous ceramides, not necessarily plant-derived supplements).
Action type:
informational_none
Target id:
/condition/cardiovascular-disease
Target name:
Established Cardiovascular Disease
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
High plasma levels of specific ceramide species are an emerging independent risk factor for adverse cardiovascular events. The impact of supplementation in this context is not fully established, warranting caution.
Actionable advice:
It is a good idea to talk to a cardiologist before starting ceramide supplements with a history of heart disease.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
This narrative review provides a concise overview of the emerging role of ceramides in cardiovascular disease... suggesting the potential use of ceramides in risk stratification and as putative therapeutic targets.
Label source:
Narrative review (2025), PMC12352314. Supports high plasma ceramides as an emerging CV risk factor/predictor.
Action type:
informational_none